Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTP4A3 | O75365 | 9/20 | 0.80 |
| ▸ | MMP13 | P45452 | 2/20 | 0.71 |
| ▸ | MMP3 | P08254 | 1/20 | 0.71 |
| ▸ | ADAMTS5 | Q9UNA0 | 3/20 | 0.71 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | TTR | P02766 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL883940 | 1.00 | PTP4A3 (0.80) | PTP4A3MMP13MMP3ADAMTS5PTPN1 | |
| SCHEMBL2064654 | 0.92 | PTP4A3 (0.75) | PTP4A3MMP13MMP3ADAMTS5PTPN1 | |
| SCHEMBL2064655 | 0.92 | PTP4A3 (0.75) | PTP4A3MMP13MMP3ADAMTS5PTPN1 | |
| SCHEMBL10090227 | 0.92 | PTP4A3 (0.75) | PTP4A3MMP13MMP3ADAMTS5PTPN1 | |
| SCHEMBL2065829 | 0.92 | PTPN1 (0.80) | PTP4A3MMP13MMP3ADAMTS5PTPN1 | |
| SCHEMBL2065828 | 0.92 | PTPN1 (0.80) | PTP4A3MMP13MMP3ADAMTS5PTPN1 | |
| SCHEMBL10090188 | 0.89 | PTP4A3 (1.00) | PTP4A3MMP13MMP3ADAMTS5PTPN1 | |
| SCHEMBL2066168 | 0.89 | PTP4A3 (1.00) | PTP4A3MMP13MMP3ADAMTS5PTPN1 | |
| SCHEMBL2066170 | 0.89 | PTP4A3 (1.00) | PTP4A3MMP13MMP3ADAMTS5PTPN1 | |
| SCHEMBL2064980 | 0.88 | PTP4A3 (0.83) | PTP4A3MMP13MMP3ADAMTS5MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042872-A1 | Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-02-12 | — | — | US | claimed |
| WO-2007081091-A1 | RHODANDSE DERIVARIVES, A PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2007-07-19 | — | — | WO | claimed |
| US-8148541-B2 | Rhodanine derivatives, a process for the preparation thereof and pharmaceutical composition containing the same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2012-04-03 | — | — | US | disclosed |
| US-20090042872-A1 | Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-02-12 | — | — | US | disclosed |
| US-6506755-B2 | 5-((2,4-bis-(4-methylphenylmethoxy)phenyl)methylene)-4-oxo-2-thioxo-3 -thiazolidineacetic acid, for example; treatment and prophylaxis of tumors and tumor metastasis | HOFFMANN-LA ROCHE INC. | 2003-01-14 | — | — | US | disclosed |
| US-20020037901-A1 | Thiazolidinecarboxyl acids | HOFFMANN-LA ROCHE INC. | 2002-03-28 | — | — | US | disclosed |
| EP-1189894-A1 | THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-27 | — | — | EP | disclosed |
| WO-2001057006-A1 | THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042872-A1 | Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same | PTPRR, PTPRG, PTPRS | PTP4A3 28/4885MMP13 2085/4885MMP3 1588/4885 |
| US-20020037901-A1 | Thiazolidinecarboxyl acids | TPMT, NAT1, THRA | PTP4A3 551/4885MMP13 4535/4885MMP3 4014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.